Overview

A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-11-22

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the pharmacokinetics (PK) of teprotumumab after a single intravenous (IV) infusion of teprotumumab in healthy Chinese participants.

Phase:

PHASE1

Details

Lead Sponsor:

Amgen

Treatments:

teprotumumab